VJHemOnc Podcast
VJHemOnc
The Video Journal of Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjhemonc.com
Episodes
Mentioned books
Dec 7, 2020 • 51min
The MDS sessions: lower-risk disease
Topics discussed in the podcast include challenges in diagnosing MDS, causes of chronic anemia, presence of LGL clones in MDS, collaboration between hematologists and pathologists, shifting trends in pathology diagnosis and challenges in training fellows, redefining goals and strategies for treating lower-risk MDS, and advancements in lower-risk myelodysplastic syndromes and future prospects.
Nov 27, 2020 • 24min
The AML Sessions: FLT3-mutated disease
Leukemia clinicians discuss FLT3-mutated AML treatment, including novel combinations and future directions. They explore mutations, targeted treatments, and the importance of maintenance therapy after transplant. Decision-making on treatment continuation is discussed, along with the potential of single-cell sequencing.
Nov 18, 2020 • 23min
The Lymphoma Sessions: highlights from iwNHL 2020
Discussion of key updates in non-Hodgkin's lymphoma, including Pembro for relapsed Hodgkin's lymphoma and benefits of PD-1 blockade. Use of PD-1 antibodies, toxicity profiles, ongoing studies, and challenges in lymphoma treatment. Importance of achieving complete remission, role of microenvironment in lymphoma, and improving treatment effectiveness. Mechanisms of action and potential combinations in lymphoma therapy, including CAR-T therapy and by-specifics.
Nov 17, 2020 • 44min
The MDS sessions: clinical trial participation, endpoints & approvals
Experts discuss challenges in MDS clinical trials. Addressing patient concerns and challenges, including remote participation. The potential of oral therapies for MDS and AML patients. Strategies to prevent MDS and extend patients' lives by targeting specific mutations.
Nov 12, 2020 • 26min
The AML Sessions: Venetoclax-based regimens
Naval Daver from MD Anderson Cancer Center leads an exciting discussion on the latest updates in the use of venetoclax-based regimens for the treatment of AML. Topics include the potential of azocididine and Venetoclax combination as a new standard of care, safety and feasibility of combination treatments, comparing regimens for AML patients, the dilemma of induction therapy, and ongoing studies and future directions in hematology.
Nov 3, 2020 • 26min
The AML Sessions: IDH inhibitors
Clinicians discuss the use of IDH inhibitors in acute myeloid leukemia (AML) and myelodysplastic syndromes, exploring combination therapies, patient selection challenges, and the potential impact of combining IDH inhibitors with chemotherapy on differentiation syndrome. Promising results have been observed in phase one and two studies, and further advancements and strategies in the field are anticipated.
Oct 8, 2020 • 36min
The AML Sessions: Immunotherapy
Leading expert in immuno-oncology, Marion Subklewe, leads a panel discussion on checkpoint inhibitors, anti-CD47 therapy, BiTEs, and CAR T-cell approaches in AML. Topics covered include progress and challenges of immunotherapy, anti CD47 drug responses, challenges of using bi-specifics, and understanding the challenges and potential of immunotherapy.
Oct 1, 2020 • 20min
Advances in CAR-T and cellular therapy from EBMT 2020: MSCs, clinical trial updates and gene-edited effector cells
Experts discuss recent updates in CAR-T and cellular therapy, including T cell engineering, CRISPR gene disruption, mesenchymal stem cells for COVID-19 pneumonia, and CAR-T cell therapy in challenging patient populations. They also analyze studies on CAR-T cell therapy, comparing management of toxicities, eligibility criteria, and durable responses. Additionally, they explore a comparison study between exocaptogen, CIBMTR, and T-stinlucil, and the potential of gene-edited effector cell therapy.
Sep 25, 2020 • 18min
SOHO 2020: Next questions in hematological malignancies
Leading experts in hematological oncology discuss future directions in research, advancements in treatment options, improvements in CAR T cell therapies, and the use of targeted therapies in hematological malignancies.
Sep 15, 2020 • 1h 1min
The MPN Sessions: pathobiology, therapeutic strategies & clinical trials
The podcast discusses the evolving management of MPNs, including COVID-19 learnings, mutations and molecular definitions of disease, interferon-based therapies, clinical trial updates, and the importance of collaboration in rare disease research.
